India Eyes Growth in Pharma Exports

 

India is setting its sights on expanding pharmaceutical exports to Russia, the Netherlands, and Brazil, according to two industry insiders. The move comes as the country looks to reduce its reliance on the United States, its largest market, amid tariff concerns and global trade uncertainties.

At present, India’s pharmaceutical industry enjoys exemption from U.S. tariffs of up to 50 percent imposed under former President Donald Trump. However, the sector remains cautious, given the unpredictability of future policy changes. The U.S. currently accounts for slightly over one-third of India’s pharmaceutical exports, valued at around $10.5 billion in fiscal 2025, driven largely by cost-effective generic versions of high-demand drugs.

To mitigate risks, the industry is now focusing on strengthening ties with other global markets. Brazil, already India’s third-largest export destination with $778 million in sales, is expected to see significant growth. Likewise, exports to the Netherlands and Russia, worth $616 million and $577 million respectively, signal promising opportunities for expansion.

Industry experts emphasize that diversification is key to safeguarding the long-term stability of India’s pharma sector. By broadening its global reach, India can balance market dependencies and tap into regions with rising demand for affordable medicine.

The United Kingdom remains the second-largest export destination with $914 million in sales, but the renewed push toward Russia, Brazil, and the Netherlands highlights India’s intent to reshape its global pharmaceutical trade map.

As one source explained, “The idea is to diversify our export chain and increase market share in other countries.”

With global demand for affordable, reliable drugs on the rise, New India Abroad notes that India’s proactive strategy positions it as a stronger, more resilient player in the international pharmaceutical market.